EA202190429A1 - Биодоступные пероральные дозированные формы - Google Patents

Биодоступные пероральные дозированные формы

Info

Publication number
EA202190429A1
EA202190429A1 EA202190429A EA202190429A EA202190429A1 EA 202190429 A1 EA202190429 A1 EA 202190429A1 EA 202190429 A EA202190429 A EA 202190429A EA 202190429 A EA202190429 A EA 202190429A EA 202190429 A1 EA202190429 A1 EA 202190429A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage forms
oral dosage
bioavailable oral
bioavailable
pharmaceutical compositions
Prior art date
Application number
EA202190429A
Other languages
English (en)
Inventor
Мандар В. Дали
Акм Насир Уддин
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA202190429A1 publication Critical patent/EA202190429A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Данное изобретение относится к биодоступным фармацевтическим композициям, имеющим повышенную дозовую нагрузку и улучшенное растворение, менее подлежащее воздействию эффекта приема пищи.
EA202190429A 2018-08-03 2019-08-02 Биодоступные пероральные дозированные формы EA202190429A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (1)

Publication Number Publication Date
EA202190429A1 true EA202190429A1 (ru) 2021-06-15

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190429A EA202190429A1 (ru) 2018-08-03 2019-08-02 Биодоступные пероральные дозированные формы

Country Status (23)

Country Link
US (1) US20210205225A1 (ru)
EP (1) EP3829544A1 (ru)
JP (1) JP2021532193A (ru)
KR (1) KR20210041589A (ru)
CN (1) CN112752570A (ru)
AR (1) AR115913A1 (ru)
AU (1) AU2019316036A1 (ru)
BR (1) BR112021001859A2 (ru)
CA (1) CA3107737A1 (ru)
CL (1) CL2021000271A1 (ru)
CO (1) CO2021001979A2 (ru)
CR (1) CR20210093A (ru)
EA (1) EA202190429A1 (ru)
EC (1) ECSP21011795A (ru)
IL (1) IL280471A (ru)
MX (1) MX2021001364A (ru)
NI (1) NI202100006A (ru)
PE (1) PE20211410A1 (ru)
PH (1) PH12021550237A1 (ru)
SG (1) SG11202100984VA (ru)
TN (1) TN2021000021A1 (ru)
TW (1) TW202019414A (ru)
WO (1) WO2020028778A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999345A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558027A1 (en) 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1737461B1 (en) 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
CA2999345A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
CA3107737A1 (en) 2020-02-06
PE20211410A1 (es) 2021-08-02
SG11202100984VA (en) 2021-02-25
CO2021001979A2 (es) 2021-03-08
IL280471A (en) 2021-03-25
WO2020028778A1 (en) 2020-02-06
KR20210041589A (ko) 2021-04-15
TW202019414A (zh) 2020-06-01
US20210205225A1 (en) 2021-07-08
EP3829544A1 (en) 2021-06-09
CR20210093A (es) 2021-05-28
MX2021001364A (es) 2021-04-13
CN112752570A (zh) 2021-05-04
TN2021000021A1 (en) 2022-10-03
NI202100006A (es) 2021-05-21
ECSP21011795A (es) 2021-03-31
JP2021532193A (ja) 2021-11-25
AU2019316036A1 (en) 2021-03-04
BR112021001859A2 (pt) 2021-04-27
AR115913A1 (es) 2021-03-10
PH12021550237A1 (en) 2021-10-11
CL2021000271A1 (es) 2021-08-20

Similar Documents

Publication Publication Date Title
EA202190429A1 (ru) Биодоступные пероральные дозированные формы
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201792591A1 (ru) Фармацевтические препараты
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201600486A1 (ru) Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201792401A1 (ru) Композиции для очищения толстого кишечника и лечения желудочно-кишечных расстройств
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201992829A1 (ru) Карбоксильные производные в качестве ингибиторов протеинкиназ
EA201992793A1 (ru) Ингибиторы протеинкиназ